ZCA
XLRN

Zeke Capital Advisors’s Acceleron Pharma XLRN Stock Holding History

Zeke Capital Advisors’s Portfolio XLRN Stock Details XLRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-2,573
Closed -$443K – 338
2021
Q3 		$443K Sell
2,573
-59
-2% -$7.72K 0.03% 158
2021
Q2 		$330K Buy
2,632
+226
+9% +$28.5K 0.02% 196
2021
Q1 		$326K Hold
2,406
– – 0.02% 192
2020
Q4 		$308K Buy
2,406
+282
+13% +$33.1K 0.03% 192
2020
Q3 		$239K Buy
+2,124
New +$211K 0.03% 187
2020
Q1 		– Sell
-11,793
Closed -$625K – 537
2019
Q4 		$625K Sell
11,793
-3,003
-20% -$137K 0.05% 329
2019
Q3 		$585K Hold
14,796
– – 0.05% 330
2019
Q2 		$608K Sell
14,796
-2,897
-16% -$120K 0.06% 309
2019
Q1 		$824K Sell
17,693
-5,514
-24% -$242K 0.08% 225
2018
Q4 		$1.01M Buy
23,207
+1,582
+7% +$79K 0.1% 199
2018
Q3 		$1.24M Buy
+21,625
New +$1.06M 0.1% 196

Zeke Capital Advisors's XLRN Position: Q4 2021 in Review

Zeke Capital Advisors sold out of Acceleron Pharma (XLRN) in Q4 2021, closing a stake of 2,573 shares — an estimated $443K sold.

Zeke Capital Advisors first reported a position in XLRN in Q3 2018 and held it in 11 quarters. The position peaked at $1.24M in Q3 2018. 1 fund tracked by Wall St. Rank holds XLRN as of Q4 2021.

  • Zeke Capital Advisors reported no remaining Acceleron Pharma position as of Q4 2021 after selling out during the quarter.
  • Zeke Capital Advisors sold 2,573 Acceleron Pharma shares in Q4 2021, an estimated $443K.
  • Zeke Capital Advisors first reported a position in Acceleron Pharma in Q3 2018 and held it in 11 quarters.
  • Zeke Capital Advisors's Acceleron Pharma position peaked at $1.24M in Q3 2018.
  • 1 fund tracked by Wall St. Rank held Acceleron Pharma as of Q4 2021.

Based on Zeke Capital Advisors's 13F filing for Q4 2021, filed 14 Feb 2022.